Bio-Rad to Acquire AbD Serotec for $69.7M

Dec 17, 2012

|

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories announced yesterday that it has signed a definitive agreement to acquire antibody manufacturer AbD Serotec for €53 million ($69.7 million) in cash.

Bio-Rad is acquiring the firm from its current parent, German company MorphoSys, and expects to complete the deal in January.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

DNA Defense Not Convincing

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Keep on Brushing

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Panda Gut Seasonality

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

This Week in PLOS

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.

Main menu